AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26360284
Drug: D-serine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-serine (60 mg/kg) given orally in divided daily doses for 16 weeks
Trial: 17304425
Drug: 5 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg/d enteral iron polymaltose complex (IPC) at 2 weeks of age
Trial: 17304425
Drug: 5 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg/d enteral iron polymaltose complex (IPC) at 4 weeks of age
Trial: 10206032
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of 1% hyperbaric bupivacaine injected over 40 sec (Group SLOW)
Trial: 10206032
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of 1% hyperbaric bupivacaine injected over 3 sec (Group FAST)
Trial: 2129376
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg anisoylated plasminogen streptokinase activator complex (BRL 26921)
Trial: 520990
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg daily etiroxate hydrochloride
Trial: 520990
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg daily etiroxate hydrochloride
Trial: 31755625
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment - on target (below 130 mm Hg)
Trial: 31755625
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment - on target (below 140 mm Hg)
Trial: 31755625
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment - on target
Trial: 26509147
Drug: CE model
RxNorm normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE model with treatment effect
Trial: 24624861
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl (normal saline solution)
Trial: 18024876
Drug: Neoadjuvant cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant cisplatin chemotherapy (NACT) before radiotherapy (RT) or chemoradiotherapy (CRT)
Trial: 18024876
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by RT or CRT
Trial: 10499382
Drug: Hypnosedation (hypnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosedation (hypnosis in combination with conscious IV sedation and local anaesthesia)
Trial: 8877349
Drug: Prednisolone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (2 mg/kg/day)
Trial: 8877349
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg/kg/day)
Trial: 1496699
Drug: Chloroquine base
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine base 25 mg/kg
Trial: 1496699
Drug: Amodiaquine base
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amodiaquine base 25 mg/kg
Trial: 29520872
Drug: peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2a 180 μg/wk × 48 weeks (group 4)
Trial: 29520872
Drug: peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2a 90 μg/wk × 24 weeks (group 1)
Trial: 29520872
Drug: peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2a 90 μg/wk × 48 weeks (group 3)
Trial: 29520872
Drug: peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2a 180 μg/wk × 24 weeks (group 2)
Trial: 24738461
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg tamsulosin + 5 mg solifenacin (mild obstruction symptom group)
Trial: 24738461
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg tamsulosin (mild obstruction symptom group)
Trial: 24738461
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg tamsulosin + 5 mg solifenacin (moderate obstruction symptom group)
Trial: 24738461
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg tamsulosin (moderate obstruction symptom group)
Trial: 10469854
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg/d) treated hemodialysis patients (+ACEi)
Trial: 22452841
Drug: OTC preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTC preparations (overall)
Trial: 22452841
Drug: 4% lidocaine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lidocaine-containing preparations
Trial: 17565490
Drug: 1-week triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week triple therapy with rabeprazole 10 mg b.i.d., amoxicillin 750 mg b.i.d., and metronidazole 250 mg b.i.d. (RAM)
Trial: 17565490
Drug: 2-week dual
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week dual therapy with rabeprazole 10 mg q.i.d. and amoxicillin 500 mg q.i.d. (RA)
Trial: 12111046
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy combined with Dietary Intervention (HRT+DIET)
Trial: 10621764
Drug: Emergency telephone
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency telephone support in addition to treatment as usual (intervention group)
Trial: 6729651
Drug: High-dose weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose weekly fractionation regimen
Trial: 6729651
Drug: Conventional daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional daily fractionation schedule
Trial: 24343275
Drug: Microencapsulated sodium
RxNorm normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microencapsulated sodium butyrate (MSB) 300 mg daily
Trial: 19938151
Drug: Hcy‐lowering therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hcy‐lowering therapy (5 mg folate and 1500 microg vitamin B(12) daily)
Trial: 19938151
Drug: Alpha‐lipoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha‐lipoic acid (alpha‐LA) therapy (1200 mg daily)
Trial: 7872875
Drug: selegiline hydrochloride
RxNorm normalized name: Selegiline Hydrochloride
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selegiline hydrochloride (10 mg/d)
Trial: 2219469
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with Mycobacterium vaccae (10^9 irradiation‐killed M. vaccae)
Trial: 7746913
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with Mycobacterium vaccae
Trial: 660709
Drug: Anti-tuberculosis drugs
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tuberculosis drugs and oral iron
Trial: 660709
Drug: Anti-tuberculosis drugs
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tuberculosis drugs only
Trial: 31618176
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of concurrent aerobic (60‐80% heart rate reserve) and resistance (40‐65% of 1RM) training
Trial: 27748083
Drug: Peficitinib 25
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib 25 mg plus MTX
Trial: 27748083
Drug: Peficitinib 50
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib 50 mg plus MTX
Trial: 27748083
Drug: Peficitinib 100
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib 100 mg plus MTX
Trial: 27748083
Drug: Peficitinib 150
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib 150 mg plus MTX
Trial: 23482645
Drug: HIV DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV DNA vaccine (4 mg) coding for clade B Gag, Pol, and Nef and clade A, B, and C Env, followed by a replication-deficient adenovirus type 5 boost (10^10 particle units)
Trial: 21490144
Drug: Phenylbutyrate administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutyrate administration
Trial: 21490144
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation during phenylbutyrate therapy
Trial: 19551673
Drug: Fixed Combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Combination (FC) therapy as second choice
Trial: 19551673
Drug: Fixed Combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Combination (FC) therapy as third choice
Trial: 19551673
Drug: Fixed Combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Combination (FC) therapy as first choice
Trial: 19551673
Drug: FC therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FC therapy overall
Trial: 19551673
Drug: Prostaglandins dosing
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandins dosing time
Trial: 16710082
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (target INR 2-3)
Trial: 15451902
Drug: AS‐3201 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS‐3201 at 5 mg/day
Trial: 15451902
Drug: AS‐3201 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS‐3201 at 20 mg/day
Trial: 3073270
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte interferon, type alpha (IFN) ointment, 7,000 Ul/gm
Trial: 17118480
Drug: Gliclazide treatment
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide treatment for 8 weeks
Trial: 15001324
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of etanercept 25 mg (subcutaneously twice a week) and oral methotrexate (up to 20 mg every week)
Trial: 18050208
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of etanercept and methotrexate
Trial: 11368288
Drug: Intravenous amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amifostine 910 mg/m2
Trial: 11368288
Drug: Intravenous amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amifostine 200 mg/m2
Trial: 11368288
Drug: Intravenous amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amifostine 340 mg/m2
Trial: 11368288
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (cisplatin 100 mg/m2 and cyclophosphamide 1000 mg/m2)
Trial: 7934153
Drug: Inhaled ipratropium
RxNorm normalized name: ipratropium Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ipratropium bromide (4 puffs of 0.02 mg)
Trial: 7934153
Drug: Intramuscular atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular atropine (0.5 mg)
Trial: 3351153
Drug: Indecainide 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indecainide 50 mg three times daily
Trial: 3351153
Drug: Indecainide 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indecainide 75 mg three times daily
Trial: 3351153
Drug: Indecainide 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indecainide 100 mg three times daily
Trial: 28966223
Drug: 12-week lifestyle
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week lifestyle modifications (combination of aerobic exercise training and dietary modification)
Trial: 28489239
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate solution
Trial: 23245290
Drug: 100 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/m2 cisplatin once every 3 weeks (arm A)
Trial: 23245290
Drug: 40 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 cisplatin once per week (arm B)
Trial: 10936467
Drug: Capecitabine at
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at a dose of 2.510 mg/m²/day (divided into two equal doses) given in an intermittent schedule (2 weeks on/1 week off)
Trial: 12959305
Drug: Fenoterol dry
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol dry powder capsules (DPC) 0.2 mg, 0.4 mg
Trial: 12959305
Drug: Fenoterol metered
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol metered dose inhaler (MDI) 0.2 mg, 0.4 mg
Trial: 12959305
Drug: Cumulative doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative doses of fenoterol DPC (0.2, 0.6, 1.4, 3.0, 6.2 mg)
Trial: 12959305
Drug: Cumulative doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative doses of fenoterol MDI (0.2, 0.6, 1.4, 3.0, 6.2 mg)
Trial: 3320307
Drug: Vincristine (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine (0.025 mg/kg intravenously for eight dosages over 12 weeks)
Trial: 3320307
Drug: OKT3 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 monoclonal antibody (first 2 weeks after transplantation)
Trial: 26937948
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous unfractionated heparin (5000-10000 units/day) until postoperative day 7 (POD7)
Trial: 26937948
Drug: Ablative surgery
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative surgery and neck dissection without heparin
Trial: 24747805
Drug: Ozone (0.30ppm)
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone (0.30ppm) inhalation during 1 hour of exercise
Trial: 24378268
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg/day for one month
Trial: 18828077
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NBI pit pattern and VPI
Trial: 17273672
Drug: Colchicine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1.5 mg/day)
Trial: 17273672
Drug: Prednisone (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (0.75 mg/kg/day)
Trial: 8637698
Drug: Single oral-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral-dose azithromycin (20 mg/kg)
Trial: 8637698
Drug: Topical tetracycline
RxNorm normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracycline eye ointment for 6 weeks
Trial: 4025792
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural anesthesia with 12-15 ml 0.25% plain bupivacaine and general anesthesia (flunitrazepam 1.5-2 mg, pancuronium bromide 0.1 mg/kg)
Trial: 4025792
Drug: Neuroleptanaesthesia (droperidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptanaesthesia (droperidol 0.1-0.2 mg/kg, fentanyl 0.01 mg/kg, pancuronium bromide 0.1 mg/kg, thiopentone 100-150 mg)
Trial: 30452422
Drug: Edasalonexent (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edasalonexent (100 mg/kg/day)
Trial: 29461363
Drug: 60 mm
RxNorm normalized name: Koromex Diaphragm Coil 60 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mm Hg capsule pressure
Trial: 29461363
Drug: 70 mm
RxNorm normalized name: ostomy supply 70 mm MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mm Hg capsule pressure
Trial: 29461363
Drug: 80 mm
RxNorm normalized name: Koromex Coil Diaphragm 80 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mm Hg capsule pressure
Trial: 29461363
Drug: 90 mm
RxNorm normalized name: ostomy supply 90 mm MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mm Hg capsule pressure
Trial: 29461363
Drug: 100 mm
RxNorm normalized name: Tenscare Electrode Pads 50x100 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mm Hg capsule pressure
Trial: 26043861
Drug: 6 servings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 servings (96 g) of WG wheat
Trial: 26043861
Drug: 3 servings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 servings (48 g) of WG wheat
Trial: 25461966
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) used as an adjunct to endodontic re-treatment
Trial: 25461966
Drug: Endodontic re-treatment
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic re-treatment alone
Trial: 19771507
Drug: Twice-weekly strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly strength training
Trial: 19753741
Drug: Microdermabrasion treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdermabrasion treatments (six sessions of aluminum oxide microdermabrasion spaced over 7 to 10-day intervals)
Trial: 19753741
Drug: Microdermabrasion treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdermabrasion treatments (six sessions)
Trial: 7553254
Drug: Bromocriptine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (2 x 2.5 mg/d for 14 days)
Trial: 7553254
Drug: Metergoline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metergoline (3 x 4 mg/d for 10 days)
Trial: 7000139
Drug: Photochemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photochemotherapy with oral 8‐MOP followed by UV‐A (PUVA)
Trial: 7000139
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule followed by A + B (pUVAB)
Trial: 25321886
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (Control)
Trial: 17392352
Drug: Infliximab dose
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab dose escalation (1.5 mg/kg increments)
Trial: 17392352
Drug: Infliximab dose
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab dose escalation(s)
Trial: 9875038
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin K1 (Konakion MM) - 2 mg at birth, repeated at 7 and 30 days
Trial: 9875038
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin K1 - 1 mg
Trial: 8040759
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy with an external insulin pump or at least three daily insulin injections, together with frequent daily blood-glucose monitoring
Trial: 8040759
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with one or two daily insulin injections and once-daily monitoring
Trial: 2723103
Drug: Listerine mouthrinse
RxNorm normalized name: Listerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listerine mouthrinse (20 ml, twice daily for 6 months)
Trial: 780039
Drug: Metaproterenol sulfate
RxNorm normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metaproterenol sulfate (10 to 20 mg, four times daily for 180 days)
Trial: 28615007
Drug: Rhythm-centred music
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm-centred music making (RMM) intervention, 10 weekly sessions
Trial: 21859932
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg azithromycin extended-release (ER)
Trial: 21859932
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg azithromycin immediate-release (IR)